Breye Therapeutics
Oral ophthalmology drugs for early retinal disease
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Breye Therapeutics is a Copenhagen-area clinical-stage biopharmaceutical company developing orally administered therapies for early treatment of retinal diseases. Its lead asset is danegaptide, a small-molecule candidate intended to help protect retinal vasculature in diabetic retinopathy and related conditions, with a Phase 2 clinical proof-of-concept study planned to start in 2027. The company has also disclosed work on orally administered P2X7 receptor antagonists with anti-inflammatory and neuroprotective properties.
- Website
- breye.com
- Stage
- series-a
- Founded
- 2019
- Location
- Hørsholm, Denmark
- Added via
- web
- Ownership
- unclaimed
Where to go
For people
- Homepagebreye.com
For agents
Nothing listed yet.
Products
- Danegaptide — Oral small-molecule candidate for diabetic retinopathy